Long-term outcomes of imatinib treatment for chronic myeloid leukemia

New England Journal of Medicine

Volumn 376, Issue 10, 2017, Pages 917-927

  Hochhaus, Andreas ^a   Larson, Richard A ^b   Guilhot, François ^c   Radich, Jerald P ^d   Branford, Susan ^e   Hughes, Timothy P ^f   Baccarani, Michele ^g   Deininger, Michael W ^h   Cervantes, Francisco ⁱ   Fujihara, Satoko ^j   Ortmann, Christine Elke ^j   Menssen, Hans D ^j   Kantarjian, Hagop ^k   O'Brien, Stephen G ^l   Druker, Brian J ^m  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF UTAH   (United States)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j NOVARTIS PHARMA AG   (Switzerland)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; IMATINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ACUTE MYELOID LEUKEMIA; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOGENETICS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LONG TERM CARE; LUNG CANCER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SARCOMA; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; CHROMOSOME ANALYSIS; CLINICAL TRIAL; INTENTION TO TREAT ANALYSIS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-OVER STUDIES; CYTARABINE; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMATINIB MESYLATE; INTENTION TO TREAT ANALYSIS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85015641837     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1609324     Document Type: Article

References (38)

1. Rumpold H, Webersinke G. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL? Curr Cancer Drug Targets 2011;11:3-19.
2. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-42.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
5. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
6. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758-65.
7. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferonalpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-84.
8. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981-7.
9. Fast Stats: an interactive tool for access to SEER cancer statistics. Silver Spring, MD: Surveillance, Epidemiology, and End Results Program, September 12, 2016 (http://seer.cancer.gov/faststats).
10. Chihara D, Ito H, Matsuda T, et al. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S. Oncologist 2012;17:1547-50.
11. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016;34:2851-7.
12. Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood 2015;126:42-9.
13. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
14. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84.
15. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2014;32:415-23.
16. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016;30:1044-54.
17. Guilhot J, Baccarani M, Clark RE, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 2012;119:5963-71.
18. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-Study IV. Leukemia 2015;29:1123-32.
19. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686-92.
20. Gratwohl A, Pfirrmann M, Zander A, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 2016;30:562-9.
21. Westin JR, Kurzrock R. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther 2012;11:2549-55.
22. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
23. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9.
24. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
25. Gambacorti-Passerini C, Brümmendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol 2014;89:732-42.
26. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96.
27. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500.
28. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-8.
29. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011;118:686-92.
30. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
31. Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016;30:48-56.
32. Hochhaus A, Rosti G, Cross NC, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2016;30:57-64.
33. Saußele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 2016;30:1638-47.
34. Hochhaus A, Saglio G, Hughes TP, et al. Impact of treatment with frontline nilotinib (NIL) vs imatinib (IM) on sustained deep molecular response (MR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 2015;126:2781. abstract.
35. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-61.
36. Guilhot F, Druker B, Larson RA, et al. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 2009;94:1669-75.
37. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107-12.
38. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014;123:2317-24.